Table_2_Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study.docx by Mats Dehlin (302586)

“…Death incidence rates were compared between the two time periods, 2006–2010 and 2011–2015.</p>Results<p>We identified 22,055 cases of incident gout and 98,946 controls, median age (Q1, Q3) 69–68 (57, 79/56, 78) years and 67.6–66.5% males. …”

Table_1_Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study.docx by Mats Dehlin (302586)

“…Death incidence rates were compared between the two time periods, 2006–2010 and 2011–2015.</p>Results<p>We identified 22,055 cases of incident gout and 98,946 controls, median age (Q1, Q3) 69–68 (57, 79/56, 78) years and 67.6–66.5% males. …”

Table_4_Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study.docx by Mats Dehlin (302586)

“…Death incidence rates were compared between the two time periods, 2006–2010 and 2011–2015.</p>Results<p>We identified 22,055 cases of incident gout and 98,946 controls, median age (Q1, Q3) 69–68 (57, 79/56, 78) years and 67.6–66.5% males. …”

Table_6_Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study.docx by Mats Dehlin (302586)

“…Death incidence rates were compared between the two time periods, 2006–2010 and 2011–2015.</p>Results<p>We identified 22,055 cases of incident gout and 98,946 controls, median age (Q1, Q3) 69–68 (57, 79/56, 78) years and 67.6–66.5% males. …”

Image_1_Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study.TIF by Mats Dehlin (302586)

“…Death incidence rates were compared between the two time periods, 2006–2010 and 2011–2015.</p>Results<p>We identified 22,055 cases of incident gout and 98,946 controls, median age (Q1, Q3) 69–68 (57, 79/56, 78) years and 67.6–66.5% males. …”

Table_3_Incident Gout: Risk of Death and Cause-Specific Mortality in Western Sweden: A Prospective, Controlled Inception Cohort Study.docx by Mats Dehlin (302586)

“…Death incidence rates were compared between the two time periods, 2006–2010 and 2011–2015.</p>Results<p>We identified 22,055 cases of incident gout and 98,946 controls, median age (Q1, Q3) 69–68 (57, 79/56, 78) years and 67.6–66.5% males. …”

Table 1_The impact of COVID-19 pandemic on nosocomial infections in the cardiac care unit of a non-epidemic hospital in China.xls by Xiang Liao (628942)

“…</p>Results<p>During the COVID-19 pandemic, the overall incidence of nosocomial infections decreased by 20.6-percent compared with the pre - pandemic period. …”

Data_Sheet_1_Influence of Axial Load and a 45-Degree Flexion Head Position on Cervical Spinal Stiffness in Healthy Young Adults.PDF by Léonie Hofstetter (11872004)

“…Post hoc analysis showed reduction of stiffness in all three measurement locations in flexion position. There was a decrease in stiffness in C2 with loading, increase in stiffness in C7 and no change in MC.…”

datasheet1_Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.docx by Yue Sun (197395)

“…As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). …”

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

A Wettability Gradient Synergistic Bionic Wedge-Shaped Track for Ultrafast and Long-Distance Spontaneous Transport of Droplets by Xinghai Zhong (21450285)

Serum sphingolipid levels associate with upcoming virologic events and HBV genotype D in a cohort of patients with HBeAg-negative HBV infection - Fig 2 by Victoria Therese Mücke (5979356)

“…<p><b>Course of (A) sphingosine, (B) sphinganine, (C) sphinganine-1-phosphate, (D) C16-dihydroceramide (C16DHC), (E) C18- and (F) C20-ceramide (C18/C20Cer) in patients with no virologic events from baseline (BL) over a follow-up (FU) period of four years (1–4).…”

Phytochemical analysis of <i>Allium Cepa</i>. by Sadia Suri (18155818)

Supplementary Material for: Current National Patterns of Comorbid Diabetes among Acute Ischemic Stroke Patients by Towfighi A. (4130227)

“…<i>Conclusions:</i> Although hospitalizations for AIS in the US decreased from 1997 to 2006, there was a steep rise in the proportion with comorbid diabetes (from 1 in 5 to almost 1 in 3). …”

Arg36Ala mutation and protease inhibitors increase the cell surface expression of PAR2-GFP without a signal peptide. by Belinda Liu (8474187)

Influence of different dietary fibre contents in the diet on feather pecking, locomotor activity and performance of laying hens by A. Patt (8879069)

“…Locomotor activity was similar across all treatments, except for a slight decrease in hens fed the 3% fibre diet at the end of the experimental period. …”